Bahrain vs Trinidad and Tobago: Prevalence rate of diabetes in adults
Bahrain
11.5
in 2014
Trinidad and Tobago
11.7
in 2014
Bahrain rank
48th
Trinidad and Tobago rank
46th
Prevalence rate of diabetes in adults over time
- Bahrain
- Trinidad and Tobago
How they compare
Trinidad and Tobago currently reports 11.7 against 11.5 in Bahrain, a difference of 0.2.
The two have swapped places 1 time across 35 shared years of data; in 1980 it was Bahrain ahead.
Bahrain ranks 48th and Trinidad and Tobago ranks 46th of 190 countries.
Bahrain has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bahrain | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 9.03 | 4.47 | 4.56 | Bahrain |
| 1990s | 9.82 | 5.84 | 3.98 | Bahrain |
| 2000s | 10.68 | 8.41 | 2.27 | Bahrain |
| 2010s | 11.3 | 10.96 | 0.34 | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of diabetes in adults, Bahrain or Trinidad and Tobago?
- Trinidad and Tobago, at 11.7 against 11.5 in Bahrain as of 2014.
- What is the difference in prevalence rate of diabetes in adults between Bahrain and Trinidad and Tobago?
- 0.2, with Trinidad and Tobago ahead.
- How many years of comparable data are there for Bahrain and Trinidad and Tobago?
- 35 years are reported by both, from 1980 to 2014.
- How do Bahrain and Trinidad and Tobago rank globally for prevalence rate of diabetes in adults?
- Bahrain ranks 48th and Trinidad and Tobago ranks 46th of 190 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of diabetes in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of people with diabetes among those aged over 18, based on general population surveys and statistical modeling. Diabetes is a risk factor for chronic complications, including cardiovascular disease, and premature death.